Retrospective screening for SARS-CoV-2 among 5,800 hospitalizations related to influenza-like illness during the 2018-19 pre-pandemic and 2019-2020 pandemic influenza seasons in the VAHNSI network, Spain.

Ainara Mira-Iglesias^{1*}, Beatriz Mengual-Chuliá^{1*}, Laura Cano¹, Javier García-Rubio¹, Miguel Tortajada-Girbés³, Mario Carballido-Fernández^{4,5}, Juan Mollar-Maseres⁶, Germán Schwarz-Chavarri⁷, Sandra García-Esteban¹, Joan Puig-Barberà, Javier Díez-Domingo^{1&}, F. Xavier López-Labrador^{1,2,&,#}, for the Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease¹

1. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), Valencia, Spain
2. Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
3. Hospital Doctor Peset, Valencia, Spain
4. Hospital General Universitario de Castellón, Castellón, Spain
5. Universidad CEU Cardenal Herrera, Castellón, Spain
6. Hospital Universitario y Politécnico La Fe, Valencia, Spain
7. Hospital General de Alicante, Alicante, Spain.

(*) Contributed equally, both authors act as first authors.
(&) Both authors act as senior authors.
(##) Members of the VAHNSI network listed at the end of the manuscript.

Corresponding author: F. Xavier López-Labrador. F.Xavier.Lopez@uv.es

Corresponding author mailing address: Virology Laboratory, Genomics & Health Area, FISABIO-Public Health. Avenida de Cataluña, 21. 46020 Valencia, Spain.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

On March 9 2020 the WHO Global Influenza Program (GIP) asked participant sites on the Global Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5,833 viral RNA archived samples collected prospectively from hospital admissions for influenza-like illness (ILI) in the Valencia Region of Spain by the VAHNSI network (4 hospitals, catchment area population 1,118,732) during the prepandemic 2018/2019 (n=4,010) and pandemic 2019/2020 (n=1,823) influenza seasons, for the presence of SARS-CoV-2. We did not find evidence for community-acquired SARS-CoV-2 infection in hospital admissions for ILI in our region before early March 2020.

Introduction

The first case of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus (SARS-CoV-2) was detected in Wuhan (Hubei province, China) at the end of 2019 and the virus rapidly spread to other Chinese provinces and countries (1). As of 3 June 2020, the World Health Organization (WHO) had already reported the presence of SARS-CoV-2 in 54 different European countries (2). In Spain, the first imported and locally acquired COVID-19 cases were detected on 31 January, and 26 February 2020, respectively (3, 4). Since then, until beginning of June, Spain accounted for 240,660 confirmed cases and 27,133 deaths. Among total registered deaths, 86% were in people aged 70 or older and 95% had previous underlying chronic conditions (5). Symptomatology described by SARS-CoV-2-infected patients was almost identical to the common influenza-like illness (ILI) symptoms (6, 7), and COVID-19 cases may have occurred in Spain earlier than previously recognized (8). Besides, there is no data available on potential SARS-CoV-2 circulation during the prepandemic 2018/2019 influenza season.

Methods

Every influenza season, from November to March/April, the Valencia Hospital Surveillance Network for the Study of Influenza and Other Respiratory Viruses (VAHNSI) network conducts a prospective active-surveillance study on respiratory viral infections in 4 hospitals, providing healthcare to 1,118,732 (22% of total) inhabitants from the Valencia Region of Spain (Figure 1). Our network is integrated in the Global Influenza Hospital Surveillance Network (GIHSN) sharing data with the WHO GIP (www.gihsn.org/). Full-time dedicated nurses screen all hospitalized patients discharged from the Emergency Department if they referred a complain possibly related to a respiratory infection. Patients are included in the study if they are resident in the catchment area of one of the participating hospitals, non-institutionalised and not discharged

from a previous admission in the last 30 days. Patients have to meet the ECDC influenza-like illness (ILI) case definition (9), defined as the presence of, at least, one systemic symptom (fever or feverishness, malaise, myalgia or headache) and, at least, one respiratory symptom (shortness of breath, sore throat or cough), with an onset of symptoms in the 7 days prior to admission. For children less than 5 years old, we only require an onset of one symptom (Table S1) in the 7 days prior to admission. Finally, patients need to be in hospital between 8 and 48 hours to be enrolled and swabbed (combined nasopharyngeal and oropharyngeal in universal transport medium), after written informed consent. Clinical and demographic characteristics from patients were obtained by a face-to-face interview or by consulting medical records.

Samples are tested in one centralized laboratory (FISABIO-Public Health) by real-time reverse-transcription polymerase chain reaction (RT-PCR) for 19 different viruses (influenza A(H1N1)pdm09, A(H3N2), B/Victoria and B/Yamagata, Respiratory Syncytial Virus (RSV) A and B, metapneumovirus, parainfluenza 1-4, rhinovirus/enterovirus, adenovirus, bocavirus, and coronavirus 229E, HKU1, NL63 and OC43). First, all available samples from the 2019/2020 season were re-analysed individually to detect SARS-CoV-2. An in-house assay was rapidly developed in February 2020 based in the WHO-Charité and U.S. CDC assays, to detect the SARS-CoV-2 E-gene (10) in multiplex together with the human cellular control RNase-P to ensure reliability of sample collection and nucleic acid extraction before RT-PCR. Only samples with RNase-P Ct values <35 were considered valid. The limit of detection of the assay was established to 35 copies using the SARS-CoV-2 E-gene as reference material either as an insert in a pCDNA plasmid (a gift from Luis Enjuanes, Coronavirus laboratory, CNB-CSIC, Madrid, Spain) or as encapsulated RNA (a gift from Charité Medical Center, Berlin, through the European Virus Archive program). Further, to investigate the possibility of SARS-CoV-2 infection earlier to fall-winter 2019 than previously recognized, we retrospectively tested in pools of 10 samples available archived viral RNAs from nasopharyngeal samples collected from 4,010 individuals admitted because of ILI during the 2018/2019 influenza season. The Ethics Research Committee of the Dirección General de Salud Pública-Centro Superior de Investigación en Salud Pública (DGSP-CSISP) previously approved the protocol for the study of respiratory viruses in the VANSI network.

Results

A total of 5,176 patients were recruited in the VANSI network between November 2019 and mid-March, 2020 and 1,843 were included after applying exclusion criteria; 1,291 of them were PCR-negative for the 19 tested seasonal viruses and the remainder 552 had at least one detectable virus. After re-testing 1,823 available samples for SARS-CoV-2, either positive or

negative for seasonal viruses, only one SARS-CoV-2 positive was detected. The result was replicated in an independent sample at the hospital laboratory. Whole-genome sequencing was performed by metagenomic sequencing with spiked primer enrichment, MSSPE (11), using a primer set described by Manning *et al.* (<https://www.protocols.io/view/sars-cov-2-enrichment-sequencing-by-spiked-primer-bc36iyre>), and showed three amino acid changes from the hCoV-19/Wuhan/WIV04/2019 strain (P323L in NSP12, L117M in NSP8, and D614G in the S protein), belonging to GISAID G clade and PANGOLIN B.1.5 lineage. The infected patient was a man in his late 70's who was admitted to hospital on early March 2020 (epidemiological week 11/2020) for acute respiratory infection with fever, cough and malaise, with symptom onset 2 days prior to admission. Co-morbidities included diabetes and a prostate adenocarcinoma, but not obesity or smoking history. During hospitalization, he was not admitted in the Intensive Care Unit (ICU) nor required mechanical ventilation or extracorporeal membrane oxygenation (ECMO). However, the patient died five days after admission. As main discharge diagnosis, the ICD10-CM code J06.9 was registered (acute upper respiratory tract infection, unspecified). Finally, all RNA pools from the 4,010 archived samples belonging to the prepandemic 2018/19 influenza season (back to September 2018) were SARS-CoV-2 RT-PCR negative.

Discussion

To our knowledge, our study is the first comprehensive screening for SARS-CoV-2 in ILI cases at the population level in the prepandemic period in Europe. We describe here the first SARS-CoV-2 admission in the Valencia Region without travel history and thus likely due to community transmission in early March, 2020. The infected patient was an old diabetic man in his late 70's who was also developing a neoplasia. It is widely known that COVID19 mainly affects elderly people (12, 13) as well as people with underlying chronic conditions (14) including diabetes in an important percentage of severe cases (15, 16). Our patient had a weak health status. Apart from his chronic conditions, he had other frailty indicators (data available upon request). Although the patient was not admitted in the ICU, he finally died 5 days after admission.

The first COVID19 cases in Spain were imported cases detected on 31 January 2020 in a German tourist in La Gomera, Canary Islands and in continental Spain on February 26, in an Italian returning from Milan (3, 4). In the Valencia Region of Spain, the first identified case was also imported (travel history to Nepal in late December 2019), detected in early February 2020 in a Hospital not covered by our surveillance network (17). Excess cases of influenza detected by analysis of primary care electronic medical records suggested an earlier circulation of SARS-

CoV-2 in other regions of Spain (8), but no laboratory identification of SARS-CoV-2 was attempted. Retrospective identification of SARS-CoV-2 was also recently suggested in swabs collected for other diagnoses or in hospitalised cases with pneumonia in Spain, so the epidemic may have gone unnoticed prior to first case of local transmission (18). Unfortunately, laboratory data on that observation are yet unpublished.

Countries from the Northern Hemisphere were already engaged in seasonal influenza control when the SARS-CoV-2 outbreak started in China. Therefore, influenza surveillance systems with wide screening windows are perfect tools to retrospectively analyse the presence of the new SARS-CoV-2, because COVID19 shares most of the ILI symptomatology such as fever and cough (12). The first study based in retrospective analysis of samples from ILI cases was performed in Wuhan, China (October 2019-January 2020), detecting the first SARS-CoV-2 cases in the first week of January 2020, concomitant with significantly higher ILI cases for the 2019–2020 winter in comparison to previous years (19). In contrast, in our network of 4 tertiary-care hospitals in South-eastern Spain (covering a population of more than 1 million), the time of the first non-travel related SARS-CoV-2 hospital admission we detect is early March 2020 and coincided with the end of the peak of influenza and other respiratory viruses (Fig. 2). In addition, ILI inpatient cases for the 2019–2020 winter were not significantly higher in comparison to previous years: average percentage inpatients with ILI were 30% in 2019-20 in our catchment area, as compared to 36% during 2018-19, with no increased ILI cases during the first 10 epidemiological weeks. Phylodynamic analyses estimated the origin of SARS-CoV-2 clusters in Spain around mid-February 2020 (21), which probably later completely replaced circulating seasonal respiratory viruses quickly in our region (Figure 2). In line with our results, SARS-CoV-2 was not detected in similar retrospective studies on inpatients limited to few cases in another region of Spain (n=170; 1 January - 25 February 2020) (20), central Italy (n=166; 1 November 2019 - 1 March 2020) (22), or in only 2/2,888 inpatients and outpatients who had negative results by routine respiratory virus testing in the United States between 1 January 2020 - 26 February 2020 (23). Collectively, our results and published data indicate that the early pandemic phase was still dominated by seasonal respiratory viruses, with very low circulation of SARS-CoV-2 in the community and probably a limited period of overlap with influenza circulation (24-25). Whether pre-existing immune memory and innate immune interference shaped SARS-CoV-2 spread deserves further investigation (24).

The first SARS-CoV-2 cases in hospital admissions in Europe had been identified at the end of January or early February 2020 as related to travel to, or to contacts with, travellers from China

(26-28). Later, retrospective analysis identified earlier cases from early or late December 2019 in Italy and France, respectively (29, 30). Some studies have suggested circulation of SARS-CoV-2 may have occurred even earlier than December 2019. A retrospective study on blood samples from Italy found SARS-CoV-2 receptor-binding domain (RBD) specific antibodies as early as September 2019 (30) but whether this observation is due to cross-reactivity with common cold coronaviruses or true SARS-CoV-2 infection is unknown. Previous retrospective sample studies based on RT-PCR testing are limited to 2020 or late December 2019 (22-24, 29, 30). In contrast, we analyzed ILI samples back to September 2018, and found no evidence supporting SARS-CoV-2 circulation in hospitalized community-acquired ILI during the prepandemic 2018/2019 or pandemic 2019/2020 influenza seasons, prior to early March 2020.

Our study has several limitations. First, the VAHNSI network was designed for detecting influenza cases, therefore COVID19 cases presenting a symptomatology different from influenza were not detected. Second, the pandemic disruption situation forced the interruption of hospital surveillance activities in mid-March, just after the declaration of the state of alarm by the Spanish Government. More cases of SARS-CoV-2 would have been detected should the study had not been stopped. Finally, it is possible that pooled testing for 2018-19 samples led to lower RT-PCR sensitivity. However, pool sizes of up to 10 samples have been proven to maintain high performance when compared with individual sample testing (23, 32).

Despite these limitations, here we show how influenza surveillance networks are a powerful resource to analyse the presence of the new respiratory viruses sharing the ILI / SARI symptomatology, because routine collection and storage of samples months (and eventually years) before the occurrence of a new virus introduction. Using these networks will allow us to expand surveillance of SARS-CoV-2, to detect unexpected pathogens in the future, and to elaborate a better map and seasonality for SARS-CoV-2 circulation during the next influenza season. The transition of influenza surveillance networks to other respiratory viruses is thus warranted.

Acknowledgements.

FXLL and BMC is supported by the CIBEResp, Instituto de Salud Carlos III, Spain. Data collection was partially supported by a grant from the Foundation for Influenza Epidemiology (FIE), which supports the Global Influenza Hospital Surveillance Network (see www.gihsn.org for more details). The sponsor did not participate in the study design, data analysis and interpretation,

208 in the writing of the manuscript or in the decision to submit the manuscript for publishing. The
209 authors thank the staff of Hospital General de Castellón, in Castellón; Hospital La Fe, in
210 Valencia; Hospital Doctor Peset, in Valencia; Hospital General de Alicante, in Alicante for their
211 support and contribution to the Valencia Hospital Network for the Study of Influenza and
212 Respiratory Viruses Disease (VAHNSI) network.

213

References

1. WHO. Novel Coronavirus (2019-nCoV). Situation report - 1. 21 January 2020: World Health Organization; 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.
2. WHO. Coronavirus disease (COVID-19) Situation Report-135: World Health Organization; 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200603-covid-19-sitrep-135.pdf?sfvrsn=39972feb_2.
3. Centro Nacional de Epidemiología, Instituto de Salud Carlos III (ISCIII). Primeros casos investigados en España por Covid-2019. Informe Covid-2019 no 1. [First Covid-19 cases in Spain. Covid-2019 report no 1]. Madrid: ISCIII; 2020. Spanish. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%201_11febrero2020_ISCIII.pdf
4. Instituto de Salud Carlos III (ISCIII). Informe sobre los casos de COVID-19 confirmados en España Informe COVID-19 no 3. [Report on confirmed COVID-19 cases in Spain. COVID-19 report no 3]. Madrid: ISCIII; 2020. Spanish. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-19.%20N%c2%ba%203_28febrero2020_ISCIII.pdf
5. Ministerio de Sanidad. Actualización nº 126. Enfermedad por el coronavirus (COVID-19) 04.06.2020: Ministerio de Sanidad. Gobierno de España.; 2020 [Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_126_COVID-19.pdf.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
7. Wang L, He WB, Yu XM, Hur DL, Bao MW, Liu HF, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *Journal of Infection*. 2020;80(6):639-45.
8. Coma E, Mora N, Prats-Urbe A, Fina F, Prieto-Alhambra D, Medina-Peralta M. Excess cases of influenza suggest an earlier start to the coronavirus epidemic in Spain than official figures tell us: an analysis of primary care electronic medical records from over 6 million people from

245 Catalonia. medRxiv 2020:2020.2004.2009.20056259. Available from:
246 <http://dx.doi.org/2020.04.09.20056259>

247 9. European Commission. Commission Implementing Decision of 8 August 2012 amending
248 Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the
249 Community network under Decision No. 2119/98/EC of the European Parliament and of the
250 Council (notified under document C(2012) 5538). European Commission. Luxembourg:
251 Publications Office of the European Union; 2012 [Available from: [https://eur-](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16)
252 [lex.europa.eu/legal-](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16)
253 [content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16).]

254 10. WHO. Molecular assays to diagnose COVID-19: Summary table of available protocols. 24
255 January 2020. [https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-](https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols)
256 [19-summary-table-of-available-protocols](https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols)

257 11. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, et al. Metagenomic sequencing
258 with spiked primer enrichment for viral diagnostics and genomic surveillance. *Nat Microbiol.*
259 2020 Mar;5(3):443-454.

260 12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus
261 Disease 2019 in China. *New England Journal of Medicine.* 2020;382(18):1708-20.

262 13. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison
263 with young and middle-aged patients. *Journal of Infection.* 2020;80(6):E14-E8.

264 14. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with
265 Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. *Aging and*
266 *Disease.* 2020;11(3):668-78.

267 15. Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the
268 severity and fatality of SARS-CoV-2 infection. *Diabetes, obesity & metabolism.* 2020.

269 16. Shi M, Chen L, Yang Y, Zhang J, Xu J, Xu G, et al. Analysis of clinical features and outcomes
270 of 161 patients with severe and critical COVID-19: A multicenter descriptive study. *Journal of*
271 *clinical laboratory analysis.* 2020:e23415.

272 17. Navarro Conde P, Alemany Monraval P, Medina Medina C, Jiménez Sánchez A, Andrés
273 Teruel JC, Ferrando Marco J, et al. Autopsy findings from the first known death from Severe
274 Acute Respiratory Syndrome SARS-CoV-2 in Spain. *Revista Española de Patología*
275 2020;53(3):188-192.

276 18. Working group for the surveillance and control of COVID-19 in Spain. The first wave of the
277 COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as
278 at 27 April 2020. *Eurosurveillance*, 25, 2001431 (2020), [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.50.2001431)
279 7917.ES.2020.25.50.2001431

280 19. Kong W-H, Li Y, Peng M-W, Kong D-G, Yang X-B, Wang L, et al. SARS-CoV-2 detection in
281 patients with influenza-like illness. *Nature Microbiology* 2020;5(5):675-678.
282 <https://doi.org/10.1038/s41564-020-0713-1>

283 20. Díez-Fuertes F, Iglesias-Caballero M, García-Pérez J, Monzón S, Jiménez P, Varona S, et al. A
284 Founder Effect Led Early SARS-CoV-2 Transmission in Spain. *Journal of Virology*
285 2021;95(3):e01583-01520.

286 21. Blanco-Suarez A, Pérez-Jové P, Escribano-Castillejo N, Ballester-Tellez M. Retrospective
287 search of SARS-CoV-2 in respiratory samples in Vallès Occidental (Barcelona, Spain) before the
288 first case was reported. *Enfermedades Infecciosas y Microbiología Clínica* 2020;38(10):511-
289 512.

290 22. Capalbo C, Bertamino E, Zerbetto A, Santino I, Petrucca A, Mancini R, et al. No Evidence of
291 SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a
292 Retrospective Surveillance. *International Journal of Environmental Research and Public Health*
293 2020;17(22).

294 23. Hogan C, Garamani N, Sahoo M, Huang C, Zehnder J, Pinsky B. Retrospective Screening for
295 SARS-CoV-2 RNA in California, USA, Late 2019. *Emerging Infectious Disease journal*
296 2020;26(10):2487.PMID: 32620178 PMCID: PMC7510744 DOI: 10.3201/eid2610.202296

297 24. Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegel K, Rentsch K, et al. Epidemiology of
298 Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired
299 Respiratory Viruses. *The Journal of Infectious Diseases* 2020 1/8/2021;222(8):1270-1279.

300 25. Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Interactions between
301 SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative
302 design. *MedRxiv* 2020:2020.09.18.20189647. <https://doi.org/10.1101/2020.09.18.20189647>.

303 26. Olsen SJ, Meng-Yu C, Yu-Lun L, Mark W, Alexis A, Clementine C, et al. Early Introduction of
304 Severe Acute Respiratory Syndrome Coronavirus 2 into Europe. *Emerging Infectious Disease*
305 *journal* 2020;26(7).

306 27. Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S, et al. Clinical and
307 virological data of the first cases of COVID-19 in Europe: a case series. *The Lancet Infectious*
308 *Diseases* 2020;20(6):697-706.

309 28. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of
310 coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February
311 2020. *2020;25(9):2000178*.

312 29. Amendola A, Bianchi S, Gori M, Colzani D, Canuti M, Borghi E, et al. Evidence of SARS-CoV-2
313 RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019. *Emerging*
314 *Infectious Disease journal* 2020;27(2).

315 30. Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, et al. SARS-
316 CoV-2 was already spreading in France in late December 2019. *International Journal of*
317 *Antimicrobial Agents* 2020;55(6):106006.

318 31. Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, et al. Unexpected
319 detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. *Tumori Journal* 2020
320 *2020/11/17:0300891620974755*.

321 32. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community
322 Transmission of SARS-CoV-2. *JAMA*; 2020. p. 1967-1969.PMID: 32250394 PMCID:
323 PMC7136853 DOI: 10.1001/jama.2020.5445.

Figure 1. Map of the covered population area in south-east Spain (red). The number of inhabitants covered by the VAHNSI network is 1,118,732.

329

330

331 **Figure 2.** Number of detections for 19 respiratory viruses in the VAHNSI network during the
 332 2019/20 influenza season by epidemiological week (November 1st 2019 to March 14th 2020).
 333 The timing for the first ILI admission positive for SARS-CoV-2 is indicated.

334